Olmetec and nighttime blood pressure in Korean adults with mild high blood pressure
Follows adults with high blood pressure taking Olmetec to see nighttime blood pressure changes.
Key facts
- Who runs it
- Daewoong Pharmaceutical Co. LTD.
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension
- Status
- Recruiting
- People taking part
- 12,000 people, planned
- Started
- 17 Sept 2025
- Expected to end
- 31 Jan 2027
- Type of study
- Observational
- Record updated
- 7 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage 1 hypertension who are newly prescribed Olmetec or Olmetec Plus in routine care. They will be followed to see how their blood pressure, including at night, changes.
- Age
- 19 years or older
- Sex
- All sexes can join
- Disease stage
- Stage 1 hypertension, diagnosed according to clinical guidelines
- Earlier treatment
- Newly prescribed Olmetec or Olmetec Plus in routine clinical practice
Main reasons for not taking part
- Secondary hypertension
- Severe hypertension that needs immediate drug treatment
- Known allergy to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs
- Pregnant, planning to become pregnant, or breastfeeding
- Severe kidney or severe liver problems
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Adults aged ≥19 years
- Patients diagnosed with stage 1 hypertension according to clinical guidelines
- Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice
- Patients who are able to undergo ambulatory blood pressure monitoring (ABPM)
- Patients who voluntarily agree to participate and provide written informed consent
Who cannot take part
- Patients with secondary hypertension
- Patients with severe hypertension requiring immediate pharmacological i-ntervention
- Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs
- Patients with severe renal impairment or severe hepatic impairment
- Patients who are pregnant, planning to become pregnant, or breastfeeding
- Patients who are unable to comply with study procedures, including ABPM
- Patients who are deemed inappropriate for participation by the investigator
Where in South Korea
- Multiple centers in Republic of KoreaSeoul, South KoreaContact: Yun Jeong KongTaking people
About the trial
What the trial wants to find out
This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.
The group in the trial
- Olmetec-Based Treatment Cohort
Patients with stage 1 hypertension who are prescribed Olmetec® or Olmetec Plus® as part of routine clinical practice will be included. Patients will be followed prospectively to assess changes in nocturnal blood pressure and blood pressure variability using ambulatory blood pressure monitoring (ABPM). No intervention beyond standard clinical care will be applied.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy of OLMETEC Tab. (or OLMETEC Plus Tab.) on Nocturnal Blood Pressure Control in Korean Patients With Stage Ⅰ Hypertension
- Plain-language title
- Olmetec and nighttime blood pressure in Korean adults with mild high blood pressureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 7 April 2026